# Randomised Evaluation of COVID-19 Therapy

> **NCT04381936** · PHASE3 · RECRUITING · sponsor: **University of Oxford** · enrollment: 70000 (estimated)

## Conditions studied

- Pneumonia

## Interventions

- **DRUG:** Lopinavir-Ritonavir
- **DRUG:** Corticosteroid
- **DRUG:** Hydroxychloroquine
- **DRUG:** Azithromycin
- **BIOLOGICAL:** Convalescent plasma
- **DRUG:** Tocilizumab
- **BIOLOGICAL:** Immunoglobulin
- **DRUG:** Synthetic neutralising antibodies
- **DRUG:** Aspirin
- **DRUG:** Colchicine
- **DRUG:** Baricitinib
- **DRUG:** Anakinra
- **DRUG:** Dimethyl fumarate
- **DRUG:** High Dose Corticosteroid
- **DRUG:** Empagliflozin
- **DRUG:** Sotrovimab
- **DRUG:** Molnupiravir
- **DRUG:** Paxlovid
- **DRUG:** Baloxavir Marboxil
- **DRUG:** Oseltamivir

## Key facts

- **NCT ID:** NCT04381936
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-03-19
- **Primary completion:** 2028-09-30
- **Final completion:** 2038-09-30
- **Target enrollment:** 70000 (ESTIMATED)
- **Last updated:** 2026-04-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04381936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04381936, "Randomised Evaluation of COVID-19 Therapy". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT04381936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*